Psychedelic Compound Shows Promise in Extending Lifespan

2025-07-12
Psychedelic Compound Shows Promise in Extending Lifespan

Emory University researchers have discovered that psilocybin, the active compound in psychedelic mushrooms, significantly delays cellular aging and extends lifespan. In a preclinical study, psilocybin increased the lifespan of human cells by over 50% and boosted survival rates in aged mice by 30%. The compound's benefits appear linked to reduced oxidative stress, improved DNA repair, and telomere preservation. This groundbreaking research suggests psilocybin could revolutionize anti-aging therapies, potentially enhancing both lifespan and quality of life in older populations.

Read more

Freedom and Hobbies Trump Achievement in Pursuit of Happiness: A Cross-Cultural Study

2025-07-06
Freedom and Hobbies Trump Achievement in Pursuit of Happiness: A Cross-Cultural Study

A large-scale study across the UK, India, and Turkey reveals that prioritizing freedom and hobbies significantly boosts well-being. Participants valuing 'hedonism' and 'self-direction' reported increased happiness, while those emphasizing 'achievement' and 'conformity' saw no such gains. Prioritizing freedom correlated with a 13% increase in well-being and improved sleep; engaging in hobbies resulted in an 8% well-being boost and a 10% reduction in stress and anxiety. The research underscores the importance of balancing life pursuits for mental health, suggesting that happiness isn't solely derived from achievement but also from freedom and leisure.

Read more
Misc

Vagus Nerve Stimulation Shows Promise in Treating Treatment-Resistant PTSD

2025-05-07
Vagus Nerve Stimulation Shows Promise in Treating Treatment-Resistant PTSD

A groundbreaking clinical study reveals that combining vagus nerve stimulation (VNS) with traditional therapy led to complete remission of PTSD in all participants up to six months post-treatment. The trial paired prolonged exposure therapy with brief VNS bursts via an implanted device, boosting neuroplasticity and sustaining remission. This offers hope for those unresponsive to conventional methods, with a larger, double-blind Phase 2 trial underway.

Read more